Expression of Signal-Transducing Zeta Chain in Peripheral Blood T Cells and Natural Killer Cells in Patients with Hodgkin's Disease in Different Phases of the Disease

References

• Oliver R. T., Nouri A. T-cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surveys 1992; 13: 17
   Google Scholar
• Clevers H., Alarcon B., Wileman T., Terhorst C. The T cell receptor/CD3 complex: a dynamic protein assembly. Annual Reviews of Immunology 1988; 6: 629–662
   PubMed Web of Science ®Google Scholar
• Geisler C., Kuhlmann J., Rubin B. Assembly, intracellular processing and the expression at the cell surface of the alpha beta T cell receptor/CD3 complex function of the CD3 zeta chain. Journal of Immunology 1989; 143: 4069–4077
   PubMed Web of Science ®Google Scholar
• Shores E. W., Love P. E. TCR zeta in T cell development and selection. Current Opinion in Immunology 1997; 9: 380–389
   PubMed Web of Science ®Google Scholar
• Sussman J. J., Bonifacino J. S., Lippincott-Schwartz J., Weissman A. M., Saito T., Klausner R. D., Ashwell N. J. D. Failure to synthesize the T-cell CD3-zeta chain: structure and function of partial T receptor complex. Cell 1988; 52: 85–95
   PubMed Web of Science ®Google Scholar
• Anderson P., Cagliuri M., O'Brien C., Manley T., Ritz J., Schlossman S. F. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by natural killer cells. Proceedings of The National Academy of Sciences of USA 1990; 87: 2274–2278
   PubMed Web of Science ®Google Scholar
• Rubin B., Martin E. P. G., Arnaud J., Delsol G., Plesner T., Ratsimbazaty A., Llobera R., Holm B., Mariame B. Expression and signal transduction of T-cell antigen receptor (TCR)/CD3 complexes on fresh or in vitro expanded T lymphocytes from patients with Hodgkin's and non-Hodgkin's lymphomas. Scandinavian Journal of Immunology 1997; 45: 715–725
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Mushoff K., Smithers D. W., Tubiana M. Report of the Committee of Hodgkin's disease staging classification. Cancer Reaserch 1971; 31: 1860–1870
   PubMed Web of Science ®Google Scholar
• Farahat N., van der Plas D., Praxedes M., Morula R., Matutes E., Catovsky D. Demonstration of cytoplasmic and nuclear antigens in acute leukemia using flow cytometry. Journal of Clinical Pathology 1994; 47: 843–849
   PubMed Web of Science ®Google Scholar
• Anderson P., Blue M. L., O'Brien C., Schlossman S. F. Monoclonal antibodies reactive with T cell receptor zeta chain: production and characterization using a new method. Journal of Immunology 1989; 143: 1899–1904
   PubMed Web of Science ®Google Scholar
• Eltringham J. R., Kaplan H. S. Impaired delayed hypersensitivity responses in 154 patients with untreated Hodgkin's disease. National Cancer Institute Monograph 1973; 36: 107–115
   PubMedGoogle Scholar
• Miller D. G., Lizardo J. G. Homologous and heterologous skin transplantation in patients with lymphomatous disease. Journal of The National Cancer Institute 1961; 26: 659–573
   Google Scholar
• Case D. R., Hansen P. A., Corrales E. Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's diseases. Cancer 1976; 38: 1807–1815
   PubMed Web of Science ®Google Scholar
• Frydecka I. Natural killer cell activity during the course of disease in patients with Hodgkin's disease. Cancer 1985; 56: 2799–1803
   PubMed Web of Science ®Google Scholar
• Damle R. N., Advani S. H., Gangal S. Impairment of proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2 producing cells in Hodgkin's disease. Cancer Immunology and Immunotherapy 1991; 34: 205–210
   PubMed Web of Science ®Google Scholar
• Frydecka I., Mazur G., Kuliczkowski K. Decreased production of interferon gamma by anti-CD3 monoclonal antibody and interleukin-2 stimulated peripheral blood mononuclear cells in Hodgkin's disease. British Journal of Haematology 1995; 91: 671–673
   PubMed Web of Science ®Google Scholar
• Mizoguchi H., O'Shea J. J., Longo D., Leoeffer C. M., McVicar D. W., Ochoa A. C. Alterations in signal tranduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1705–1798
   Web of Science ®Google Scholar
• Bianchi A., Mariani S., Beggiato E., Borrione P., Peola S., Boccarodo M., Pileri A., Massaia M. Distribution of T-cell signalling molecules in human myeloma. British Journal of Haematology 1997; 97: 815–820
   PubMed Web of Science ®Google Scholar
• Buggins A. G.G., Hirst W. J. R., Pagliuca A., Mufti G. J. Variable expression of CD3-zeta and associated protein kinases in lymphocytes from patients with myeloid malignancies. British Journal of Haematology 1998; 100: 784–792
   PubMed Web of Science ®Google Scholar
• Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O'Shea J. J., Kudoh S., Klein E., Bukowski R. M., Ochoa A. C. Loss of T-cell receptor zeta chain and p56 Ick in T-cell infiltrating human renal cell carcinoma. Cancer Research 1993; 53: 5613–5616
   PubMed Web of Science ®Google Scholar
• Gunji Y., Hori S., Aoe T., Asano T., Ochiai T., Isono K., Saito T. High frequency of cancer patients with abnormal assembly of the T cell receptor CD3 complex in peripheral blood T lymphocytes. Japanese Journal of Cancer Research 1994; 85: 1189–1192
   PubMedGoogle Scholar
• Holm G., Mellstedt H., Bjorkholm M. Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer 1976; 37: 751–762
   PubMed Web of Science ®Google Scholar
• Kono K., Ressing M. E., Brandt R. M. P., Melief C. J. M., Potkul R. K., Andersson B., Petersson M., Kast W. M., Kiessling R. Decreased expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with cervical cancer. Clinical Cancer Research 1996; 2: 1825–1828
   PubMed Web of Science ®Google Scholar
• Lai P., Rabinowich H., Crowley-Nowick P. A., Bell M. C., Mantovani G., Whiteside T. Alterations in expression and function of signal transducing proteins in tumor associated T and natural killer cells in patients with ovarian carcinoma. Clinical Cancer Research 1996; 2: 1263–1274
   PubMedGoogle Scholar
• Massaia M., Attisato C., Beggiato E., Bianchi A., Pileri A. Correlation between disease activity and T-cell CD3 zeta chain expression in B-cell lymphoma. British Journal of Haematology 1994; 88: 886–888
   PubMed Web of Science ®Google Scholar
• Matsuda M., Petersson M., Lenkei R., Taupin J. L., Magnusson I., Hellstedt H., Anderson P., Kiessling R. Alterations in signal transducing molecules of T cells and NK cells in colorectal tumor infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Interntional Journal of Cancer 1995; 61: 765–777
   PubMed Web of Science ®Google Scholar
• Renner C., Ohnesorge S., Held G., Bauer S., Jung W., Pfitzenmeier J. P., Pfeundschuh M. T cells from patients with Hodgkin's diseases have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996; 88: 236–241
   PubMed Web of Science ®Google Scholar
• Rossi E., Matutes E., Morilla R., Owusu-Ankomah K., Hefferman A. M., Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996; 10: 494–497
   PubMed Web of Science ®Google Scholar
• Roskow M. A., Suzuki N., Gan Y., Sixbey J. W., Ng C Yc, Kimbrough S., Hudson M., Brenner M. K., Heslop H. E., Roonney C. M. Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's diseases. Blood 1988; 91: 2925–2934
   Google Scholar
• Sjoberg J., Andersson M., Palucka K., Bjorgholm M., Pisa P. (1998) Higher expression of CD3-associated zeta-chain in tumor associated T lymphocytes in Hodgkin's diseases. Fourth International Symposium on Hodgkin's Lymphoma, KolnGermany, March 28-April-1, 1988, 39, Leukemia and Lymphoma, 29, suppl. 1
   Google Scholar
• Liberati A. M., Ballatori E., Fizotto M., Schipps M., Pronetti M. G., Di Marzio R., Pecci A., Bisscetii L., Sharetti R., Cini L., Grignani F. Immunologic profile in patients with Hodgkin's disease in complete remission. Cancer 1987; 59: 1906–1913
   PubMed Web of Science ®Google Scholar
• Aoe T., Okamoto Y., Saito T. Activated macrophages induce structural abnormalities of the T cell receptor CD3 complex. Journal of Experimental Medicine 1995; 181: 1881–1886
   PubMed Web of Science ®Google Scholar
• Kono K., Salazar F., Petersson M., Hansson J., Masucci G., Wasserman K., Nakazawa T., Anderson P., Kiessling R. Hydrogene peroxide secreted by tumor derived macrophages down-regulates signal transducing zeta molecules and inhibits tumor specific T-cell and NK-cell mediated cytotoxicity. European Journal of Immunology 1996; 10: 199–215
   Google Scholar
• Hansson J., Asca A., Ersson U., Hermodsson S., Hell-Strand K. Induction of apoptosis in NK cells by monocyte derived reactive oxygen metabolites. Journal of Immunology 1996; 156: 42–47
   PubMed Web of Science ®Google Scholar
• Fu E. J., Arca M. J., Hain J. M., Krinock R., Rado J., Cameron M. J., Chang A. E., Sondask V. K. Tumor induced suppression of antitumor reactivity and depression of TCR zeta expression in tumor-draining lymph-node lymphocytes: possible relationship to the TH2 pathway. Journal of Immunotherapy 1997; 20: 111–122
   PubMed Web of Science ®Google Scholar